NCT02500251View on ClinicalTrials.gov

Belimumab Impacting Transplant Eligibility

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

June 30, 2018

Study Completion Date

August 31, 2018

Conditions
Renal Transplant Rejection
Interventions
DRUG

belimumab

Belimumab will be administered per study protocol.

DRUG

Bortezomib

Bortezomib will be administered per study protocol.

DRUG

Rituximab

Rituximab will be administered per study protocol.

DRUG

Plasmapheresis

Plasmapheresis will be administered per study protocol.

Trial Locations (2)

45219

The Christ Hospital, Cincinnati

45267

University of Cincinnati, Cincinnati

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

E. Steve Woodle

OTHER

NCT02500251 - Belimumab Impacting Transplant Eligibility | Biotech Hunter | Biotech Hunter